Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Neoplasms 52Neoplasm Metastasis 49Leukemia, Myeloid, Acute 48Colorectal Neoplasms 48Breast Neoplasms 44Prostatic Neoplasms 38Multiple Myeloma 34Ovarian Neoplasms 32Recurrence 29Melanoma 28Pancreatic Neoplasms 27Lymphoma, Non-Hodgkin 26Squamous Cell Carcinoma of Head and Neck 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 22Endometrial Neoplasms 22Triple Negative Breast Neoplasms 21Glioblastoma 20Carcinoma, Renal Cell 20Lung Neoplasms 19Advanced Solid Tumors 19Stomach Neoplasms 18Small Cell Lung Carcinoma 18Sarcoma 18Carcinoma, Hepatocellular 17Brain Neoplasms 17Lymphoma, B-Cell 14Esophageal Neoplasms 13Advanced Solid Tumor 13

Interventions

peposertib 1pembrolizumab 1liposomal doxorubicin 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Histamine H2 Antagonists 1Famotidine 1Doxorubicin 1Biopsy 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Dermatofibrosarcoma × 30 days × Clear all
NCT06789172 2026-05-22

INVOKE

Epkin

Phase 1 Recruiting
166 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Sarcoma, Colorectal Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡